Novo Nordisk's 24.9% Stock Surge Validates Pharma's Pivot From Internal R&D to AI Partnerships
Novo Nordisk's stock jumped 24.9% after the company shut its internal cell therapy unit and licensed its Parkinson's program to AI-enabled Cellular Intelligence. The move signals a structural shift: pharma incumbents are exiting expensive in-house research for asset-light, AI-accelerated models. NVIDIA's BioNeMo platform and a wave of specialized biological foundation models are now the industry's core drug discovery infrastructure.
Salvado•